Home LiteratureArticle Details
PMID: 21734724 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Cyclin D as a therapeutic target in cancer.

Nature reviews. Cancer ·Vol. 11 ·No. 8 ·2011-07-07 ·Pages 558-72

Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL

Abstract

Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?

MeSH Terms
Cyclin D/genetics,physiology Humans Neoplasms/drug therapy,genetics Oncogenes/genetics,physiology Polymorphism, Genetic
Chemicals
Cyclin D
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Musgrove Elizabeth A
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney NSW 2010, Australia.
Caldon C Elizabeth
Barraclough Jane
Stone Andrew
Sutherland Robert L
References (183)
183 references, click to expand
  1. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.
    Mol Cancer Ther. 2010 May;9(5):1265-73 PMID: 20423997
  2. CDK inhibitors: positive and negative regulators of G1-phase progression.
    Genes Dev. 1999 Jun 15;13(12):1501-12 PMID: 10385618
  3. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
    J Biol Chem. 1997 Dec 26;272(52):33327-37 PMID: 9407125
  4. Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity.
    Oncogene. 2000 Nov 23;19(50):5703-11 PMID: 11126356
  5. Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells.
    Br J Cancer. 1999 Dec;81(7):1174-81 PMID: 10584879
  6. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.
    Cancer Res. 2009 Feb 1;69(3):810-8 PMID: 19155308
  7. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer.
    Cancer Res. 2009 Jul 1;69(13):5553-9 PMID: 19549910
  8. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.
    Leukemia. 2009 Jul;23(7):1320-8 PMID: 19225534
  9. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
    Cancer Chemother Pharmacol. 2009 Jul;64(2):425-9 PMID: 19280191
  10. Molecular pathogenesis and a consequent classification of multiple myeloma.
    J Clin Oncol. 2005 Sep 10;23(26):6333-8 PMID: 16155016
  11. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
    Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2190-5 PMID: 16461912
  12. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.
    Cancer Res. 2005 Dec 15;65(24):11354-60 PMID: 16357142
  13. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.
    Int J Exp Pathol. 2005 Dec;86(6):347-63 PMID: 16309541
  14. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
    Cancer Cell. 2010 Jul 13;18(1):63-73 PMID: 20609353
  15. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.
    Anticancer Res. 2010 Apr;30(4):1279-85 PMID: 20530440
  16. Requirement for CDK4 kinase function in breast cancer.
    Cancer Cell. 2006 Jan;9(1):23-32 PMID: 16413469
  17. The structure of CDK4/cyclin D3 has implications for models of CDK activation.
    Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4171-6 PMID: 19237555
  18. Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma.
    Mol Cell Biol. 2005 Nov;25(22):9985-95 PMID: 16260612
  19. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer.
    Cancer Cell. 2008 Jul 8;14(1):68-78 PMID: 18598945
  20. Cell cycle, CDKs and cancer: a changing paradigm.
    Nat Rev Cancer. 2009 Mar;9(3):153-66 PMID: 19238148
  21. Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy.
    J Biol Chem. 2005 Jan 7;280(1):768-76 PMID: 15509582
  22. Biological determinants of endocrine resistance in breast cancer.
    Nat Rev Cancer. 2009 Sep;9(9):631-43 PMID: 19701242
  23. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.
    J Clin Invest. 2010 Jul;120(7):2528-36 PMID: 20577054
  24. Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis.
    J Biol Chem. 2010 Apr 23;285(17):12695-705 PMID: 20159986
  25. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
    Mol Cancer Ther. 2008 Sep;7(9):2876-83 PMID: 18790768
  26. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
    Clin Cancer Res. 2004 Aug 1;10(15):5038-47 PMID: 15297405
  27. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability.
    Cancer Res. 1999 May 15;59(10):2297-301 PMID: 10344732
  28. Tissue microarray analysis of cyclin D1 gene amplification and gain in colorectal carcinomas.
    Tumour Biol. 2004 Jul-Aug;25(4):157-60 PMID: 15557752
  29. Cyclin D1 and breast cancer.
    Breast. 2006 Dec;15(6):718-27 PMID: 16675218
  30. Cyclin D1 gene (CCND1) mutations in endometrial cancer.
    Oncogene. 2003 Sep 4;22(38):6115-8 PMID: 12955092
  31. Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo.
    Cell Cycle. 2009 Sep 1;8(17):2802-9 PMID: 19652536
  32. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
    J Biol Chem. 2001 May 18;276(20):16617-23 PMID: 11278443
  33. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  34. Somatic variation and cancer: therapies lost in the mix.
    Hum Genet. 2011 Jul;130(1):79-91 PMID: 21643984
  35. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss.
    Cancer Res. 2010 Oct 15;70(20):8149-58 PMID: 20736363
  36. Cyclin D1 governs adhesion and motility of macrophages.
    Mol Biol Cell. 2003 May;14(5):2005-15 PMID: 12802071
  37. Cyclin-dependent kinases regulate the antiproliferative function of Smads.
    Nature. 2004 Jul 8;430(6996):226-31 PMID: 15241418
  38. Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation.
    Genes Dev. 2002 Jul 15;16(14):1792-805 PMID: 12130539
  39. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
    J Med Chem. 2000 Jul 27;43(15):2797-804 PMID: 10956187
  40. Coordinated regulation of differentiation and proliferation of embryonic cardiomyocytes by a jumonji (Jarid2)-cyclin D1 pathway.
    Development. 2011 May;138(9):1771-82 PMID: 21447557
  41. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor.
    Proc Natl Acad Sci U S A. 1999 May 11;96(10):5382-7 PMID: 10318892
  42. A census of amplified and overexpressed human cancer genes.
    Nat Rev Cancer. 2010 Jan;10(1):59-64 PMID: 20029424
  43. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
    Oncogene. 1998 Jun 4;16(22):2865-78 PMID: 9671407
  44. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Cancer Res. 2008 Jul 15;68(14):5519-23 PMID: 18632601
  45. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Clin Cancer Res. 2004 Nov 15;10(22):7764-74 PMID: 15570011
  46. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?
    Nat Rev Cancer. 2004 Dec;4(12):948-55 PMID: 15573116
  47. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
    Breast Cancer Res. 2009;11(5):R77 PMID: 19874578
  48. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.
    Mol Cell Biol. 1997 Sep;17(9):5338-47 PMID: 9271411
  49. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
    Cancer Res. 2001 Mar 15;61(6):2782-7 PMID: 11289162
  50. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling.
    Mol Cell Biol. 2006 Jun;26(11):4240-56 PMID: 16705174
  51. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.
    Mol Cancer Ther. 2009 Sep;8(9):2517-25 PMID: 19755512
  52. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.
    Am J Pathol. 2010 Jun;176(6):2607-15 PMID: 20395447
  53. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Science. 2004 Feb 6;303(5659):844-8 PMID: 14704432
  54. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.
    Cancer Res. 2010 Mar 1;70(5):2105-14 PMID: 20179208
  55. The activities of cyclin D1 that drive tumorigenesis.
    Trends Mol Med. 2004 Apr;10(4):158-62 PMID: 15059606
  56. Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
    Mol Cell Biol. 2011 Jul;31(13):2566-76 PMID: 21536647
  57. Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration.
    J Biol Chem. 2008 Mar 14;283(11):7007-15 PMID: 18180298
  58. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo.
    Oncogene. 2007 Mar 22;26(13):1829-39 PMID: 17043661
  59. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen.
    Nature. 2010 Jan 21;463(7279):374-8 PMID: 20090754
  60. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.
    Cell Cycle. 2010 Oct 15;9(20):4153-63 PMID: 20948315
  61. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
    Cancer Cell. 2010 Oct 19;18(4):329-40 PMID: 20951943
  62. Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability.
    Mol Cell Biol. 2008 Dec;28(23):7245-58 PMID: 18809569
  63. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Clin Cancer Res. 2008 Mar 15;14(6):1767-74 PMID: 18347178
  64. Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II.
    J Biol Chem. 2003 Feb 21;278(8):6355-62 PMID: 12482873
  65. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.
    Mol Carcinog. 2009 Oct;48(10):953-64 PMID: 19415719
  66. Bexarotene and erlotinib for aerodigestive tract cancer.
    J Clin Oncol. 2005 Dec 1;23(34):8757-64 PMID: 16314636
  67. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
    Clin Cancer Res. 2005 Aug 15;11(16):6075-86 PMID: 16115953
  68. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.
    Lung Cancer. 2007 Jan;55(1):1-14 PMID: 17070615
  69. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
    Br J Cancer. 2004 May 17;90(10):1942-8 PMID: 15138475
  70. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
    Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 PMID: 16894390
  71. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
    Cancer Cell. 2003 Feb;3(2):185-97 PMID: 12620412
  72. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.
    Oncogene. 2010 Sep 9;29(36):5103-12 PMID: 20581865
  73. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer.
    Int J Cancer. 2004 Jun 10;110(2):194-200 PMID: 15069681
  74. CDK-independent activation of estrogen receptor by cyclin D1.
    Cell. 1997 Feb 7;88(3):405-15 PMID: 9039267
  75. Molecular pathogenesis of head and neck squamous cell carcinoma.
    Eur Arch Otorhinolaryngol. 2003 Oct;260(9):502-8 PMID: 12736744
  76. Systematic validation of predicted microRNAs for cyclin D1.
    BMC Cancer. 2009 Jun 18;9:194 PMID: 19538740
  77. Requirement for cyclin D3 in lymphocyte development and T cell leukemias.
    Cancer Cell. 2003 Dec;4(6):451-61 PMID: 14706337
  78. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
    Blood. 2007 Sep 15;110(6):2075-83 PMID: 17537993
  79. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.
    Clin Cancer Res. 2009 Sep 1;15(17):5338-49 PMID: 19706803
  80. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma.
    Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1668-72 PMID: 16884382
  81. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
    Clin Cancer Res. 2003 Apr;9(4):1446-52 PMID: 12684418
  82. Update on the molecular biology of mantle cell lymphoma.
    Hematol Oncol. 2006 Mar;24(1):22-7 PMID: 16402392
  83. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization.
    Clin Cancer Res. 2006 Aug 1;12(15):4720-9 PMID: 16899623
  84. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.
    Mol Cancer. 2007 Apr 02;6:24 PMID: 17407548
  85. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.
    Oncogene. 2009 Feb 19;28(7):1016-27 PMID: 19079343
  86. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.
    Nature. 1994 Jun 23;369(6482):669-71 PMID: 8208295
  87. Cell cycle kinases as therapeutic targets for cancer.
    Nat Rev Drug Discov. 2009 Jul;8(7):547-66 PMID: 19568282
  88. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    J Clin Oncol. 2010 Nov 1;28(31):4769-77 PMID: 20921461
  89. The landscape of somatic copy-number alteration across human cancers.
    Nature. 2010 Feb 18;463(7283):899-905 PMID: 20164920
  90. Cyclin D1: polymorphism, aberrant splicing and cancer risk.
    Oncogene. 2006 Mar 13;25(11):1620-8 PMID: 16550162
  91. Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity.
    Cell Cycle. 2008 Aug;7(15):2299-305 PMID: 18677114
  92. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication.
    Genes Dev. 2007 Nov 15;21(22):2908-22 PMID: 18006686
  93. Emerging roles of E2Fs in cancer: an exit from cell cycle control.
    Nat Rev Cancer. 2009 Nov;9(11):785-97 PMID: 19851314
  94. Linking cyclins to transcriptional control.
    Gene. 2002 Oct 16;299(1-2):35-55 PMID: 12459251
  95. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis.
    Cancer Cell. 2010 Jan 19;17(1):65-76 PMID: 20129248
  96. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.
    Oncogene. 2009 Apr 16;28(15):1812-20 PMID: 19287456
  97. Tyrosine kinases as targets for cancer therapy.
    N Engl J Med. 2005 Jul 14;353(2):172-87 PMID: 16014887
  98. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.
    Nature. 2011 Jun 08;474(7350):230-4 PMID: 21654808
  99. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
    Mol Cell Biol. 1995 May;15(5):2600-11 PMID: 7739541
  100. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation.
    J Biol Chem. 2005 Apr 8;280(14):13793-800 PMID: 15649889
  101. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
    Br J Cancer. 2011 Jun 7;104(12):1862-8 PMID: 21610706
  102. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
    Cancer Res. 2006 Aug 1;66(15):7661-7 PMID: 16885367
  103. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.
    Blood. 2007 Jun 1;109(11):4599-606 PMID: 17299095
  104. Minireview: Cyclin D1: normal and abnormal functions.
    Endocrinology. 2004 Dec;145(12):5439-47 PMID: 15331580
  105. DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression.
    Cancer Cell. 2008 Aug 12;14(2):166-79 PMID: 18691551
  106. Impact of differential cyclin D1 expression and localisation in prostate cancer.
    Br J Cancer. 2007 Mar 26;96(6):970-9 PMID: 17375037
  107. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1.
    Genes Dev. 1998 Nov 15;12(22):3488-98 PMID: 9832502
  108. Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor alpha-mediated transcription.
    Int J Oncol. 2010 Jan;36(1):39-48 PMID: 19956831
  109. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
    Oncogene. 2010 Jul 15;29(28):4018-32 PMID: 20473330
  110. Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor.
    Mol Cell Biol. 2007 Oct;27(20):7125-42 PMID: 17698582
  111. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
    Mol Cancer Ther. 2006 Nov;5(11):2644-58 PMID: 17121911
  112. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression.
    Cancer Res. 2006 Dec 15;66(24):11649-58 PMID: 17178859
  113. Nuclear cyclin D1: an oncogenic driver in human cancer.
    J Cell Physiol. 2009 Aug;220(2):292-6 PMID: 19415697
  114. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.
    Cell. 2003 Aug 8;114(3):323-34 PMID: 12914697
  115. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
    Cancer Res. 1999 Jul 15;59(14):3505-11 PMID: 10416617
  116. Alternative cyclin D1 splice forms differentially regulate the DNA damage response.
    Cancer Res. 2010 Nov 1;70(21):8802-11 PMID: 20940395
  117. Tailoring to RB: tumour suppressor status and therapeutic response.
    Nat Rev Cancer. 2008 Sep;8(9):714-24 PMID: 19143056
  118. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.
    Clin Cancer Res. 2009 Jun 1;15(11):3654-62 PMID: 19470724
  119. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy.
    Cancer Prev Res (Phila). 2011 Jun;4(6):779-82 PMID: 21636543
  120. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.
    Cancer Cell. 2006 Jan;9(1):13-22 PMID: 16413468
  121. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer.
    Oncogene. 1999 Mar 18;18(11):1983-91 PMID: 10208420
  122. Cell-specific responses to loss of cyclin-dependent kinases.
    Oncogene. 2007 Jul 5;26(31):4469-77 PMID: 17297466
  123. Cyclin D1 induction of cellular migration requires p27(KIP1).
    Cancer Res. 2006 Oct 15;66(20):9986-94 PMID: 17047061
  124. The BATTLE trial: personalizing therapy for lung cancer.
    Cancer Discov. 2011 Jun;1(1):44-53 PMID: 22586319
  125. Crystal structure of human CDK4 in complex with a D-type cyclin.
    Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4166-70 PMID: 19237565
  126. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function.
    Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11567-72 PMID: 16864783
  127. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
    Cancer Res. 2010 Apr 15;70(8):3228-38 PMID: 20354191
  128. Cyclin-dependent kinase pathways as targets for cancer treatment.
    J Clin Oncol. 2006 Apr 10;24(11):1770-83 PMID: 16603719
  129. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.
    Clin Med Insights Oncol. 2010 Apr 20;4:15-34 PMID: 20567632
  130. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
    Breast Cancer Res Treat. 2005 May;91(2):145-51 PMID: 15868442
  131. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation.
    Cell Cycle. 2005 Feb;4(2):330-8 PMID: 15684604
  132. Cyclin D1 determines mitochondrial function in vivo.
    Mol Cell Biol. 2006 Jul;26(14):5449-69 PMID: 16809779
  133. mTOR and cancer: insights into a complex relationship.
    Nat Rev Cancer. 2006 Sep;6(9):729-34 PMID: 16915295
  134. The role of cell cycle regulatory proteins in the pathogenesis of melanoma.
    Pathology. 2006 Aug;38(4):287-301 PMID: 16916716
  135. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
    Mol Cancer Ther. 2004 Nov;3(11):1427-38 PMID: 15542782
  136. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
    Mod Pathol. 2006 Jul;19(7):999-1009 PMID: 16648863
  137. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.
    J Biol Chem. 2006 Nov 24;281(47):35942-53 PMID: 17001081
  138. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.
    Blood. 2008 Feb 1;111(3):1193-200 PMID: 18003885
  139. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.
    Biomed Pharmacother. 2006 Jul;60(6):269-72 PMID: 16887322
  140. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
    Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11501-6 PMID: 20534551
  141. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
    Hum Pathol. 2008 Dec;39(12):1792-801 PMID: 18715616
  142. Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis.
    J Cell Sci. 2002 Jan 1;115(Pt 1):153-64 PMID: 11801733
  143. Cyclins: roles in mitogenic signaling and oncogenic transformation.
    Growth Factors. 2006 Mar;24(1):13-9 PMID: 16393691
  144. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.
    Mol Cell Biol. 1999 Oct;19(10):7011-9 PMID: 10490638
  145. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation.
    J Biol Chem. 2006 Jun 16;281(24):16347-53 PMID: 16613857
  146. CDK inhibitors: cell cycle regulators and beyond.
    Dev Cell. 2008 Feb;14(2):159-69 PMID: 18267085
  147. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.
    Nat Med. 2008 Nov;14(11):1271-7 PMID: 18931683
  148. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
    Nat Rev Cancer. 2007 Oct;7(10):750-62 PMID: 17891190
  149. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice.
    Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):194-9 PMID: 11134518
  150. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.
    Cell. 2004 Aug 20;118(4):493-504 PMID: 15315761
  151. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
    Nature. 2008 Oct 23;455(7216):1061-8 PMID: 18772890
  152. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1.
    Oncogene. 2006 Oct 12;25(47):6291-303 PMID: 16732330
  153. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
    Clin Cancer Res. 2003 Oct 15;9(13):4730-4 PMID: 14581343
  154. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative.
    Int J Cancer. 2000 Oct 1;88(1):77-81 PMID: 10964085
  155. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1.
    Curr Biol. 1997 Jan 1;7(1):71-80 PMID: 8999999
  156. Mouse development and cell proliferation in the absence of D-cyclins.
    Cell. 2004 Aug 20;118(4):477-91 PMID: 15315760
  157. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo.
    Cell Cycle. 2008 Jul 15;7(14):2215-24 PMID: 18635970
  158. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
    Breast Cancer Res Treat. 2008 May;109(2):325-35 PMID: 17653856
  159. Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
    Mol Cell Biol. 1994 Mar;14(3):2077-86 PMID: 8114739
  160. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.
    Clin Cancer Res. 1999 Oct;5(10):2810-9 PMID: 10537346
  161. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
    Cancer Prev Res (Phila). 2011 Jun;4(6):818-28 PMID: 21636548
  162. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells.
    Mol Cell Biol. 2010 Feb;30(3):694-710 PMID: 19933848
  163. Molecular prognostic markers in pancreatic cancer: a systematic review.
    Eur J Cancer. 2005 Oct;41(15):2213-36 PMID: 16146690
  164. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment.
    J Biol Chem. 2005 Apr 29;280(17):16934-41 PMID: 15713663
  165. The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.
    Am J Pathol. 2004 Mar;164(3):1031-8 PMID: 14982856
  166. Living with or without cyclins and cyclin-dependent kinases.
    Genes Dev. 2004 Nov 15;18(22):2699-711 PMID: 15545627
  167. Cyclin D1 in low-dose radiation-induced adaptive resistance.
    Oncogene. 2008 Dec 4;27(53):6738-48 PMID: 18695676
  168. Cyclin D1 in breast cancer pathogenesis.
    J Clin Oncol. 2005 Jun 20;23(18):4215-24 PMID: 15961768
  169. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all.
    Nat Rev Mol Cell Biol. 2006 Sep;7(9):667-77 PMID: 16921403
  170. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.
    Mol Cell Biol. 2000 Jan;20(2):672-83 PMID: 10611246
  171. Initiating oncogenic event determines gene-expression patterns of human breast cancer models.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72 PMID: 12011455
  172. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
    Clin Cancer Res. 2011 Mar 15;17(6):1591-602 PMID: 21278246
  173. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
    Oncogene. 2007 Aug 2;26(35):5060-9 PMID: 17334399
  174. Role of Cdk4 in lymphocyte function and allergen response.
    Cell Cycle. 2010 Dec 15;9(24):4922-30 PMID: 21150327
  175. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors.
    Mol Cell Biol. 1996 Dec;16(12):6623-33 PMID: 8943316
  176. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1.
    J Cell Biol. 1994 May;125(3):625-38 PMID: 8175885
  177. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
    Clin Cancer Res. 2004 Jul 15;10(14):4680-7 PMID: 15269140
  178. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
    Clin Cancer Res. 1999 Aug;5(8):2069-76 PMID: 10473088
  179. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
    Blood. 2006 Sep 1;108(5):1744-50 PMID: 16690963
  180. Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3beta-mediated cyclin D1 overexpression.
    Oncogene. 2010 Aug 26;29(34):4826-37 PMID: 20562919
  181. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner.
    Mol Endocrinol. 2001 May;15(5):797-811 PMID: 11328859
  182. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis.
    Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2773-81 PMID: 18843022
  183. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.
    Cell. 1992 Oct 16;71(2):323-34 PMID: 1423597
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3090
Published
2011-07-07
Epub
2011-00-07
Pages
558-72
Language
English
Region
England
NLM ID
101124168
Subset
IM
External Links
PubMed source DOI: 10.1038/nrc3090 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2